Globus Medical Inc (GMED) — SEC Filings
Globus Medical Inc (GMED) — 28 SEC filings. Latest: 8-K (Mar 23, 2026). Includes 12 8-K, 6 10-Q, 6 SC 13G/A.
View Globus Medical Inc on SEC EDGAR
Overview
Globus Medical Inc (GMED) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 23, 2026: Globus Medical Inc. filed an 8-K on March 23, 2026, reporting on Item 5.02, which typically covers changes in directors or officers and their compensation. This filing also includes Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). While the specific details of
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 2 bullish, 26 neutral. The dominant filing sentiment for Globus Medical Inc is neutral.
Filing Type Overview
Globus Medical Inc (GMED) has filed 12 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of GMED's 19 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2.11B |
| Net Income | $397.3M |
| EPS | $0.88 |
| Debt-to-Equity | 0.16 |
| Cash Position | $371.8M |
| Operating Margin | 14.7% |
| Total Assets | $5.10B |
| Total Debt | $696.8M |
Key Executives
- David Demski
- Daniel Scavilla
- David C. Johnson
Industry Context
Globus Medical operates in the highly competitive and rapidly evolving medical device industry, specifically within the musculoskeletal and neuromodulation sectors. Key trends include the increasing demand for minimally invasive surgical techniques, advancements in robotic surgery, and the growing adoption of implantable devices for pain management and neurological conditions. The industry is characterized by significant R&D investment, stringent regulatory oversight, and consolidation through mergers and acquisitions.
Top Tags
corporate-governance (5) · 10-Q (5) · 8-K (4) · financials (4) · Medical Devices (3) · Globus Medical (3) · executive-changes (2) · compensation (2) · Earnings Growth (2) · 10-K (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Sales (Q3 2025) | $769.0M | Increased 22.9% from $625.7M in Q3 2024 |
| Net Income (Q3 2025) | $119.0M | Increased 129.5% from $51.8M in Q3 2024 |
| Net Sales (YTD Q3 2025) | $2.11B | Increased 13.4% from $1.86B in YTD Q3 2024 |
| Net Income (YTD Q3 2025) | $397.3M | Increased 419.5% from $76.5M in YTD Q3 2024 |
| Bargain Purchase Gain | $114.4M | Result of Nevro acquisition for YTD Q3 2025 |
| Cash and Cash Equivalents | $371.8M | Decreased from $784.4M at Dec 31, 2024, due to financing activities |
| Senior Convertible Notes Repaid | $449.9M | Significant cash outflow in YTD Q3 2025 |
| Common Stock Repurchases | $255.5M | Significant cash outflow in YTD Q3 2025 |
| Net Cash Provided by Operating Activities | $504.9M | Strong operating cash flow for YTD Q3 2025 |
| Diluted EPS (Q3 2025) | $0.88 | Increased from $0.38 in Q3 2024 |
| Revenue | $650.5M | Increased 15.2% from Q2 2024 |
| Net Income | $95.2M | Increased 12.8% from Q2 2024 |
| Revenue Growth | 15.2% | Year-over-year increase for Q2 2025 |
| Net Income Growth | 12.8% | Year-over-year increase for Q2 2025 |
| Total Assets | $5.8B | As of June 30, 2025, up from $5.6B at Dec 31, 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Globus Medical Inc (GMED)?
Globus Medical Inc has 28 recent SEC filings from Jan 2024 to Mar 2026, including 12 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GMED filings?
Across 28 filings, the sentiment breakdown is: 2 bullish, 26 neutral. The dominant sentiment is neutral.
Where can I find Globus Medical Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Globus Medical Inc (GMED) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Globus Medical Inc?
Key financial highlights from Globus Medical Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GMED?
The investment thesis for GMED includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Globus Medical Inc?
Key executives identified across Globus Medical Inc's filings include David Demski, Daniel Scavilla, David C. Johnson.
What are the main risk factors for Globus Medical Inc stock?
Of GMED's 19 assessed filings, 0 were flagged high-risk, 6 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Globus Medical Inc?
Forward guidance and predictions for Globus Medical Inc are extracted from SEC filings as they are enriched.